Camilla Bo’ is an Italian freelance journalist and stylist. After two years of study in Paris she returned to her native Rome to study architecture. The art of critique proved more fruitful for Camilla and she began to write for the Association of Art and Critic about art and design and on her personal blog Choufouchouf. Focusing on the relation and communication between fashion and art, she decided to follow her creative nature not only giving a voice to the library she has on her laptop but also as inspiration for editorials. She’s now based in London, attending the course of «Art Direction for Fashion» at the Central Saint Martins College of Art.
If you have a weight problem or have body image issues, then you have probably heard of fat burners of all types. There are just as many fat burners for women on the market as there are fat burners for men. Most people are overwhelmed when they realize how many fat burners are on the market. After absorbing all this information, then you have to ask yourself which ones actually work. It’s important to learn how to choose the right fat burner product so that it actually works for you as an individual. Below is vital information that can help you make your choice regarding fat burning supplements.
A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was months in the nab-paclitaxel-gemcitabine group as compared with months in the gemcitabine group (hazard ratio for death, ; 95% confidence interval [CI], to ; P<). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was months in the nab-paclitaxel-gemcitabine group, as compared with months in the gemcitabine group (hazard ratio for disease progression or death, ; 95% CI, to ; P<); the response rate according to independent review was 23% versus 7% in the two groups (P<). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.